Yüklüyor......
Efficacy of rFIXFc versus rIX-FP for the Treatment of Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PROLONG-9FP Trials
PURPOSE: In patients with hemophilia B, treatment with extended half-life (EHL) recombinant factor IX allows for longer dosing intervals while providing equal or superior bleeding protection compared with standard half-life products. This enables flexible, individualized treatment schedules, which r...
Kaydedildi:
| Yayımlandı: | J Blood Med |
|---|---|
| Asıl Yazarlar: | , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Dove
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8286734/ https://ncbi.nlm.nih.gov/pubmed/34285621 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JBM.S312885 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|